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Background: The ubiquitin-proteasome system and macroautophagy (hereafter referred to autophagy) are two
complementary pathways for protein degradation. Emerging evidence suggests that proteasome inhibition might
be a promising approach for tumor therapy. Accumulating data suggest that autophagy is activated as a
compensatory mechanism upon proteasome activity is impaired.
Method: Autophagy activation was measured using acridine orange staining and LC3 transition. Cell viability and
apoptosis were measured using MTT assay and flow cytometry, respectively. Beclin 1 expression vectors or shRNA
against Beclin 1 (shBeclin 1) were transfected to investigate the role of Beclin 1 in autophagy activation and
cytotoxicity of ovarian cancer cells induced by proteasome inhibitors.
Results: Proteasome inhibitors suppressed proliferation and induced autophagy in ovarian cancer cells. Neither
phosphoinositide 3-kinase (PI3K) inhibitors nor shRNA against Beclin 1 could abolish the formation of acidic
vacuoles and the processing of LC3 induced by proteasome inhibitors. Moreover, Beclin 1 overexpression enhanced
anti-proliferative effects of proteasome inhibitors in ovarian cancer cells.
Conclusions: For the first time, the current study demonstrated that proteasome inhibitors induced PI3K and Beclin
1-independent autophagy in ovarian cancer cells. In addition, this study revealed autophagy-independent tumor
suppressive effects of Beclin 1 in ovarian cancer cells.
Keywords: Proteasome inhibition, Beclin1, Ovarian cancerBackground
The ubiquitin-proteasome system serves as a major intra-
cellular pathway for protein degradation in mammalian
cells [1]. Many proteins involved in cancer cell growth and
survival are regulated by proteasomal degradation [2]. In
this connection, proteasome inhibitors constitute a novel
class of anti-tumor agents with pre-clinical and clinical evi-
dence of activity against hematologic malignancies and
solid tumors [3]. Macroautophagy (hereafter is referred as
autophagy) is an evolutionarily conserved catabolic process
by which cell destructs its cytoplasmic content and
organelles through the lysosomal machinery [4]. Autophagy* Correspondence: 892207391@qq.com
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reproduction in any medium, provided the oris initiated by the formation of a double-membrane bound
vacuole (autophagosome), which sequesters cytosolic
proteins and organelles such as mitochondria, endoplasmic
reticulum. Autophagosomes are short-lived organelles that
fuse with acidic lysosomes to produce autolysosomes where
the sequestered content is degraded by lysosomal enzymes,
and amino acids and sugars are recycled into the cytosol
for reuse. Morphologically, autophagy is characterized by
the formation of LC3+ double-membrane bound autopha-
gosomes, the accumulation of acidic vesicular organelles
and autolysosomes in the cytoplasm [5-7]. Autophagy was
originally recognized as a crucial prosurvival mechanism to
supply the cell with nutrients under unfavorable grown
conditions [4]. It is now clear that autophagy plays a crucial
role in development, programmed cell death and aging
[4,8-10]. Dysregulation of autophagy has been involved inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 (See legend on next page.)
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Figure 1 Growth inhibition and apoptosis of ovarian cancer cells induced by proteasome inhibitors. A, SKOV3, OVCAR3 or A2870 cells
were treated with the indicated concentrations of MG132 for 24 h, and cell viability was measured using MTT assay. B, SKOV3, OVCAR3 or A2870
cells were treated with 5 μM of MG132 for 24 h, and nuclear morphology was analyzed using Hoechst 33258 staining. C, SKOV3, OVCAR3 or
A2870 cells were treated with vehicle, bortezomib (BZ), epoxomicin (Epox), lactacystin (Lacta), or MG132 for 24 h, and Western blot analysis was
performed using the indicated antibodies. D, SKOV3, OVCAR3 or A2870 cells were treated with the indicated concentrations of MG132 for 24 h,
and apoptotic cells were measured using Annexin V and PI double staining followed by flow cytometry. *, P<0.01.
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autophagy can have both suppressive and promoting roles
in carcinogenesis makes it an attractive target in cancer re-
search [10]. As a tumor suppressing mechanism, autophagy
serves as an alternative to apoptosis to eliminate trans-
formed cells [4]. Moreover, tumorigenesis is often asso-
ciated with a reduced autophagy while genes that are
involved in the execution of autophagy are found to be
tumor suppressors [4]. On the other hand, autophagy may
facilitate tumor growth and survival by providing tumor
cells a selective advantage to therapy resistance and aggres-
siveness [4,10]. As two important intracellular pathways
for protein degradation in mammalian cells, autophagy
functions complementarily with the ubiquitin-proteasome
system [1,11], and suppression of UPS can activate auto-
phagy [12-20].
Emerging evidence shows that autophagy is important
in the regulation of cancer development and progression
[10]. However, the role of autophagy is complicated and
autophagy may have opposing consequences in cells.
On one hand, autophagy may protect tumor cells
from nutrient deprivation and hypoxia; on the other
hand, autophagy defect is associated with the development
of cancer [8,21].
Beclin 1 is a tumor suppressor gene product that
allosterically activates the class III phosphatidylinositol 3-
kinase (PI3KC3), which is essential for the recruitment of
other autophagy-related gene (Atg) proteins to the phago-
phore assembly site (PAS) to initiate autophagosome for-
mation [22,23]. The BH3 binding groove of Bcl-XL/Bcl-2
binds the BH3 helix of Beclin1, preventing Beclin1 from
recruitment to the PI3KC3 complex [24,25]. Recently,
accumulating studies suggest that autophagy can also
occur in a Beclin1-independent manner and in this case
PI3K inhibitors fails to suppress it [26-30].
Here we reported that proteasome inhibitors induced
cell death and autophagy in ovarian cancer cells. It was of
note that MG132-induced autophagy was accompanied by
a reduction of Beclin 1. In addition, we reported that
proteasome inhibitors elicited autophagy even in shRNA
against Beclin 1 (shBeclin 1) transfected cells, or in the
presence of PI3Ks inhibitors, indicating that proteasome
inhibitors caused Beclin 1/PI3Ks-independent autophagy.
Furthermore, we demonstrated that Beclin 1 overexpres-
sion enhanced proteasome inhibitors-mediated cell death
of ovarian cancer cells. Collectively, these data suggestedthat Beclin 1 sensitized ovarian cancer cells to proteasome
inhibitors in an autophagy-independent manner.
Methods
Culture of multiple cancer cell lines
SKOV3, OVCAR3 and A2870 ovarian cancer cell lines
were maintained in DMEM (Sigma-Aldrich, Saint Louis,
MO) supplemented with 10% fetal bovine serum (FBS,
Sigma-Aldrich, Saint Louis, MO).
Chemicals
MG132, epoxomicin, PSI and lactacystin were purchased
from Calbiochem (La Jolla, CA). 0.02% DMSO was used
as vehicle control.
Cell viability assays
For cell viability assays, cells were plated in 96-well
dishes (1 × 104 cells per well) and the next day were
treated with or without apoptosis inducing agents in 10%
FBS-containing media and grown over a 24-h period. Cell
viability was assessed using the 3-(4,5-dimethylthiazol-2-
thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) assay
(Chemicon, Bedford, MA) according to the manufacturer’s
instruction.
Detection of apoptotic cell death
For cell death assays, cells were washed twice in
phosphate-buffered saline and then stained with Annexin
V-FITC (Biovision, Mountainview, CA) and propidium
iodide (PI, Sigma-Aldrich) according to the manufacturer’s
instructions. After staining with Annexin V-FITC and PI,
samples were analyzed by fluorescence-activated cell
scanner (FACScan) flow cytometer (Becton Dickinson,
Franklin Lakes, NJ).
Acridine orange staining for acidic vesicular organelles
Acridine orange was added at a final concentration of
1μg/ml for a period of 15 min. Pictures were obtained
with a fluorescence microscope (Olympus) equipped
with a digital camera (Olympus).
Western blot analysis
Cells were lysed in lysis buffer (20 mM Tris–HCl, 150 mM
NaCl, 2 mM EDTA, 1% Triton-X100 and protease
inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO). Cell


































































Figure 2 Induction of autophagy by proteasome inhibitors in ovarian cancer cells. A, SKOV3, OVCAR3 or A2870 cells were treated with
vehicle or 5 μM of MG132 for 24 h, and the formation of acidic vacuoles were analyzed using AO staining. B, SKOV3, OVCAR3 or A2870 cells were
treated with the indicated concentrations of MG132 for 24 h, Western blot analysis was performed to investigate LC3 transition. C, OVCAR3 were
treated with vehicle, BZ, Epox, Lacta or MG132 in the absence or presence of bafiloymycin A1 for 24 h, and LC3 transition was measured using
Western blot analysis. D, OVCAR3 were transfected with a scramble shRNA or shRNA specific against Atg7 (shAtg7) for 24 h, then treated with
5 μM of MG132 for additional 24 h, and Western blot was performed.
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were separated using 12% SDS-PAGE and transferred to
PVDF membrane (Millipore Corporation, Billerica, MA).Caspase-3 activity assay
For caspases-3 enzymatic assays, 50 μg whole-cell extract
was added to reaction buffer containing 25 mm HEPES
(pH 7.5), 4 mm CHAPS, 1mm dithiothreitol (DTT), 1
mm phenylmethylsulfonyl fluoride (PMSF), 2 μg/ml apro-
tinin, 1 μg/ml leupeptin, and 2 μg/ml pepstatin, to
achieve a total reaction volume of 500 μl. Ac-DEVD-
AMC (Ac-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin;Alexis Biochemicals, San Diego, CA) was added to the
mixture at a concentration of 100 μM and incubated for 1
h at 37°C. Cleavage of the substrate was measured by
fluorescence spectrometer (HTS 7000; PerkinElmer,
Boston, MA) using an excitation and emission wavelength
of 360 and 465 nm, respectively. The activities were
expressed as fluorescence increase per microgram of
protein.DNA construction and transfection
Beclin 1 plasmid was constructed by PCR and cloned










































Figure 3 Autophagy demonstrated little effects on cytotoxicity
induced by MG132 in ovarian cancer cells. A, OVCAR3 were
transfected with scramble shRNA or shRNA specific against Atg7
(shAtg7) for 24 h, then treated with 5 μM of MG132 for additional
24 h, and cell viability was measured using MTT assay. B, SKOV3,
OVCAR3 or A2870 cells were treated with 5 μM of MG132 in the
presence of chloroquine or bafilomycin A1 for 24 h, and cell viability
was measured using MTT assay. N.S., p>0.05.
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Beclin 1 (shBeclin 1) or Atg7 (shAtg7) was purchased
from Open Biosystems. Cells were transfected with
Lipofectamine 2000 reagent (Invitrogene) as instructed by
the supplier.Statistics
The statistical significance of the difference was analyzed
by ANOVA and post hoc Dunnett’s test. Statistical
significance was defined as p<0.05. All experiments were
repeated three times, and data were expressed as the
mean±SD (standard deviation) from a representative
experiment.Results
Proteasome inhibitors inhibited proliferation and induced
apoptosis in ovarian cancer cells
To study the effect of blockade of ubiquitin-proteasome
system on proliferation of ovarian cancer cells, SKOV3,
OVCAR3 and A2870 cells were treated with proteasome
inhibitor MG132 at concentrations ranging from 0 to
10 μM for 24 h, the cell viability was determined using
the MTT assay. MG132 significantly reduced cellproliferation in these cell lines in a concentration-
dependent manner (Figure 1A). To determine the inci-
dence of apoptosis morphologically, we stained the nuclei
of 5 μM MG132 treated SKOV3, OVCAR3 and A2870
cells with Hoechst 33258. Apoptotic morphological char-
acteristics such as chromatin condensation and nuclear
fragmentation were detected in these ovarian cancer cells
treated with 5 μM of MG132 (Figure 1B). Western blot
confirmed that proteasome inhibitors including MG132,
epoxomicin (Epox), Lactacystin (Lacta) and bortezomib
(BZ) elicited cleavage of PARP in SKOV3, OVCAR3 and
A2870 cells (Figure 1C). Annexin V-FITC and PI double
staining followed by flowcytometry also confirmed that
5 μM of MG132 caused apoptosis of SKOV3, OVCAR3
and A2870 cells (Figure 1D).
Proteasome inhibitors induced autophagy in ovarian
cancer cells
Under the light microscope, it was apparent that MG132
induced the formation of large vacuoles in the cytoplasm
of ovarian cancer cells (data not shown). To determine
the effect of MG132 on autophagy, we analyzed the
accumulation of acidic vesicular organelles using the
acridine orange (AO) staining. AO emitted bright red
fluorescence in acidic vesicles but fluoresced green in
cytoplasm and nucleus [6]. Vital staining of SKOV3,
OVCAR3 or A2870 cells with AO revealed the appearance
of acidic vesicular organelles after 5 μM of MG132 treat-
ment (Figure 2A). Since the conversion of LC3 protein
from LC3-I (the cytosolic form) to LC3-II (the membrane
bound form) correlates with the extent of autophagy [5],
we also analyzed the conversion of cytosolic LC3-I into
LC3-II Western blot analysis. Results showed that MG132
induced LC3 transition in a dose-dependent manner
in SKOV3, OVCAR3 or A2870 cells, respectively
(Figure 2B). Similar like MG132, Western blot analysis
also demonstrated that other proteasome inhibitors
including BZ, Epox and Lacta also induced LC3 transition
in OVCAR3 cells (Figure 2C). Since both autophagy in-
duction and impaired autophagic degradation ascribes to
accumulation of LC3-II [31], the effect of inhibiting
lysosomal turnover of autophagosome contents by bafilo-
mycin A1 [31] were also examined. Preventing lysosomal
degradation by bafilomycin A1 cotreatment significantly
increased LC3-II transition elicited by proteasome
inhibitors (Figure 2C). In addition, knockdown of
Atg7, a well-known autophagy essential gene, blocked
LC3-II transition elicited by MG132 (Figure 2D).
Autophagy demonstrated little effects on MG132-
mediated cytotoxicity in ovarian cancer cells
To investigate the potential role of autophagy in cytotox-
icity induced by proteasome inhibitors, OVCAR3 cells













































































































Figure 4 PI3KC3-independent autopahgy induced by proteasome inhibitors in ovarian cancer cells. A, Ovarian cancer cells were treated
with 5 μM of MG132 in the absence or presence of wortmannin (WT) or 3-MA, and AVs formation was analyzed using AO staining. B, Ovarian
cancer cells were treated with 5 μM of MG132 in the absence or presence of WT or 3-MA, and LC3 transition was analyzed using Western blot
analysis. C, OVCAR3 cells were treated with the indicated proteasome inhibitor in the absence or presence of WT or 3-MA, and AVs formation was
measured using AO staining. D, OVCAR3 cells were treated with the indicated proteasome inhibitor (PI) in the absence or presence of WT or
3-MA, and LC3 transition was analyzed using Western blot analysis.
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strated that shAtg7 demonstrated little effects on viability
of OVCAR3 upon MG132 exposure (Figure 3A).
Cotreatment with chloroquine or bafilomycin A1 to
suppress autophagy at the late stage also demonstrated
little effect on MG132-induced cytotoxicity of ovarian
cancer cells (Figure 3B).
Wortmannin (WT) and 3-MA demonstrated no effect on
proteasome inhibitors-induced autophagy in ovarian
cancer cells
To investigate the role of autophagy in proteasome
inhibitors-mediated cytotoxicity of ovarian cancer
cells, we managed to suppress autophagy activated
by proteasome inhibitors using PI3Ks inhibitors.Unexpectedly, AO staining demonstrated that neither
WT nor 3-MA suppressed MG132-induced accumulation
of acid vacuoles in SKOV3, OVCAR3 and A2870 cells
(Figure 4A). Western blot analysis confirmed that
WT or 3-MA could not inhibit the conversion of
LC3-I to LC3-II in MG132-treated SKOV3, OVCAR3
or A2870 cells (Figure 4B). To investigate whether
proteasome inhibitors generally induced PI3K-
independent autophagy, we tested some other prote-
asome inhibitors including BZ, Epox and Lacta in
OVCAR3 cells. AO staining demonstrated that all
these proteasome inhibitors induced accumulation of
acidic vacuoles, neither WT nor 3-MA could block
acidic vacuoles accumulation (Figure 4C). Western
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Figure 5 (See legend on next page.)
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Figure 5 Beclin 1-independent autophagy induced by proteasome inhibitors in ovarian cancer cells. A, Ovarian cancer cells were treated
with the indicated concentrations of MG132, and Western blot was performed using the indicated antibodies. B, Ovarian cancer cells were
treated with the indicated concentrations of MG132, Beclin 1 mRNA was measured using real-time PCR. C, OVCAR3 cells were transfected with
control shRNA or shRNA against Beclin 1 (shBeclin 1), then treated with the indicated proteasome inhibitor, and LC3 transition was analyzed
using Western blot analysis. D, OVCAR3 cells were transfected with control shRNA or shRNA against Beclin 1 (shBeclin 1), then treated with the
indicated proteasome inhibitor, and AVs formation was measured using AO staining.
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proteasome inhibitors (Figure 4D).
Proteasome inhibitors elicited Beclin 1-independent
autophagy in ovarian cancer cells
As Beclin 1 is essential for the PI3K complex [32], obser-
vations that neither WT nor 3-MA was able to inhibit
the increase in autophagosomes induced by proteasome
inhibitors prompted us to confirm the role of Beclin 1 in
proteasome inhibitors-induced autophagy. Western blot
analysis demonstrated that MG132 reduced Beclin 1
expression in a dose-dependent manner in SKOV3,
OVCAR3 and A2870 cells (Figure 5A). Real-time RT-
PCR found that MG132 had no obvious effects on Beclin
1 mRNA expression (Figure 5B), suggesting that MG132
suppresses Beclin 1 at the translational or posttransla-
tional level. To confirm the involvement of Beclin 1 in
autophagy elicited by proteasome inhibition, Beclin 1 ex-
pression levels were further reduced by shRNA specific
against Beclin 1 (shBeclin 1) in OVCAR3 cells. Western
blot analysis confirmed that with some different extents,
proteasome inhibitors reproducibly reduced Beclin 1 ex-
pression (Figure 5C). Specific shRNA against Beclin 1
(shBeclin 1) effectively reduced Beclin 1 levels under
basal condition or upon exposure to proteasome inhibi-
tors (Figure 5C). Importantly, transition of LC3-I to
LC3-II (Figure 5C) and acidic vacuoles formation
(Figure 5D) elicited by proteasome inhibitors was not
affected by shBeclin 1.
Overexpression of Beclin 1 enhanced cytotoxicity of
ovarian cancer cells induced by proteasome inhibitors
To determine the influence of Beclin 1 in cytotoxicity of
ovarian cancer cells induced by proteasome inhibitors,
OVCAR3 cells were transfected with Beclin 1 eukaryotic
expression vector. Compared to parental and pcDNA3.1
vector-transfected controls, a higher expression of Beclin
1 protein was detected in the Beclin 1-transfected
OVCAR3 cells, and reduction of Beclin1 protein by pro-
teasome inhibitors was suppressed by Beclin 1 transfec-
tion (Figure 6A). Overexpression of Beclin 1 significantly
enhanced proteasome inhibitors-induced cytotoxicity of
ovarian cancer cells, as assessed by cleavage of PARP
(Figure 6A), MTT assay (Figure 6B), nuclei staining with
Hoechst 33258 (Figure 6C), and caspase 3 activityassay (Figure 6D). In addition, analysis of PARP cleavage
(Figure 6E) and MTT assay (Figure 6F) demonstrated
that Beclin 1 overexpression also increased MG132-
induced cytotoxicity of SKOV3 cells and A2870 cells.Discussion
Two major proteolytic systems for the clearance of pro-
teins are conserved in eukaryotic cells: the first is the
UPS and the second is autophagy. Both UPS and
autophagy are involved in most aspects of normal
physiology and development. They are also impli-
cated in multiple pathological states, such as cancer,
neurodegeneration and aging. Although UPS and
autophagy are generally thought to be independent
from each other, recent investigations now support
that the two proteolytic systems are functionally
linked, and autophagy is activated and plays a com-
pensatory role when UPS function is impaired [12-20].
Autophagy is frequently activated in cancer cells in
response to chemo- or radiotherapy [33,34]. The contri-
bution of autophagy to cell death induced by therapy
generally remains controversial as autophagy protects
some cancers against chemotherapy yet sensitizes
others to chemotherapy-mediated cytotoxicity [33,34].
In the current study, we confirmed that proteasome
inhibitors activated autophagy in ovarian cancer cells,
as evidenced by accumulation of acidic vacuoles, in-
crease in LC3-II transition. However, suppression of
autophagy at the early stage by knockdown of Atg7,
as well as at the late stage by cotreatment with chror-
oquine or bafilomycin A1 demonstrated little effects
on cytotoxicity of ovarian cancer cells mediated by pro-
teasome inhibition. The different role of autophagy in
chemotherapy-induced cytotoxicity might represent cell-
specific and/or stress-specific response. The dual roles of
autophagy in survival and cell death require further
clarification.
Beclin 1, the mammalian homologue of the yeast
Atg6 was initially identified as a Bcl2-interacting
tumor suppressor [35]. It is now known that Beclin 1
cooperates with several cofactors to activate lipid
kinase PI3KC3, which is essential for recruitment of
other Atg proteins to form autophagic vacuoles or
autophagosomes [32]. However, several recent studies
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Figure 6 Sensitizing effects of Beclin 1 overexpression on proteasome inhibitors-mediated cytotoxicity of ovarian cancer cells. A,
OVCAR3 cells were transfected with mock or Beclin 1 eukaryotic plasmid for 24 h, then treated with the indicated proteasome inhibitors for
additional 24 h, and Western blot was performed using the indicated antibodies. A representative image was presented, and the ratios vs that of
control (normalized by GAPDH) was noted at the bottom of the Beclin 1 image. B, OVCAR3 cells were transfected with mock or Beclin 1
eukaryotic plasmid for 24 h, then treated with the indicated proteasome inhibitors for additional 24 h, and cell viability was measured using MTT
assay. C, OVCAR3 cells were transfected with mock or Beclin 1 eukaryotic plasmid for 24 h, then treated with the indicated proteasome inhibitors
for additional 24 h, and nuclei morphology was measured using Hoechst 33258 staining. D, OVCAR3 cells were transfected with mock or Beclin 1
eukaryotic plasmid for 24 h, then treated with the indicated proteasome inhibitors for additional 24 h, and caspase-3 activity was measured. E,
SKOV3 and A2870 cells were transfected with mock or Beclin 1 eukaryotic plasmid for 24 h, then treated with 5 μM of MG132 for additional 24 h,
and Western blot was performed. F, SKOV3 and A2870 cells were transfected with mock or Beclin 1 eukaryotic plasmid for 24 h, then treated with
5 μM of MG132 for additional 24 h, and cell viability was analyzed using MTT assay. *, P<0.01.
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named as non-canonical autophagy [26-30]. For ex-
ample, resveratrol, Parkinsonian neurotoxin MPP+
and a small compound targeting the BH3 binding
groove of Bcl-XL has been shown to activate autop-
hagy in a Beclin 1-independent manner in breast
cancer MCF7 cells, neuroblastoma cells and HeLa
cells, respectively [26-30]. In the current study, for
the first time, we reported that proteasome inhibitors
elicited PI3KC3 and Beclin 1-independent autophagy
in ovarian cancer cells, as evidenced by neither PI3Ks
inhibitor wortmannin or 3-MA, nor shRNA against
Beclin 1 could block accumulation of acidic vacuoles
and increase in LC3-II transition induced by prote-
asome inhibitors. The mechanisms by which autop-
hagosome formation can bypass the Beclin 1-PI3KC3
pathway remain to be clarified in the future.
Genetic analysis has revealed that Beclin 1 is implicated
in tumorigenesis and plays a role in cellular proliferation
[8,22,36,37]. It has been reported that overexpression of
Beclin 1 activates autophagy and reduces the tumorige-
netic potential of breast cancer cells [22]. In addition,
overexpression of Beclin 1 has been shown to enhance
the sensitivity of cervix and gastric cancer cells to
chemotherapeutic drugs [38,39]. On the contrary, he-
terozygous disruption of Beclin 1 in mice increases
cellular proliferation and results in spontaneous malig-
nancies [37]. Consistent with previous reports [38,39], in
the current study, flowcytometry analysis and caspase 3
activity assay indicated that a greater in crease in apoptosis
was observed in Beclin 1-transfected cells than the mock-
transfected cells. Controversially, Beclin 1 knockdown
has been shown to promote apoptosis induced by
doxorubicin in HepG2 cells [40]. These reports there-
fore suggest that Beclin 1 may modulate apoptosis in
cell-specific and stimuli-specific patterns. It has been
generally believed that Beclin 1 functions as a haploinsuf-
ficient tumor suppressor via autophagy activation [22,41].
However, in the current study, we found that proteasome
inhibitors activated autophagy in a Beclin 1-independent
manner. In addition, suppression of autophagy both atthe early stage and at the late stage had no obvious effects
on cytotoxicity mediated by proteasome inhibitors. On
the contrary, Beclin 1 overexpression enhanced respon-
siveness of ovarian cancer cells to proteasome inhibitors-
mediated cytotoxicity, indicating that Beclin 1 exerts
autophagy-independent tumor suppressive effect in ovar-
ian cancer cells upon exposure to proteasome inhibitors.
Therefore, mechanisms underlying enhancing effects of
Beclin 1 on chemosensitivity may be multifactorial, and
the mechanisms by which Beclin 1 sensitizes ovarian
caner cells to proteasome inhibition require further
investigation.
Conclusions
Proteasome inhibitors elicit PI3KC3 and Beclin 1 inde-
pendent autophagy in ovarian cancer cells. In addition,
Beclin 1 sensitizes ovarian cancer cells to proteasome in-
hibition in autophagy-independent manner.
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